Ara
Toplam kayıt 7, listelenen: 1-7
68-months progression-free survival with crizotinib treatment in a patient with metastatic ALK positive lung adenocarcinoma and sarcoidosis: A case report
(Sage Publications Ltd, 2020)
Introduction Lung cancer still ranks first among the most common and most lethal cancers today. The most common subtype is non-small cell lung cancer, and in this group, adenocarcinoma has the worst prognosis. EGFR, ROS1 ...
The Social Media Disorder and Ostracism in Adolescents: (OSTRACA- SM Study)
(Aves, 2020)
Objective: Social media disorder (SMD) is defined as a behavioral addiction and has been associated with depression, loneliness, narcissism, low self-esteem, poor sleep quality, and low academic performance. Ostracism is ...
Demographical and Clinical Features of Marginal Zone Lymphomas: A Retrospective Study of Turkish Oncology Group (TOG)
(Springer India, 2020)
Marginal zone lymphomas (MZLs) are rare and indolent subtypes of non-Hodgkin lymphomas, and their clinical behaviours are heterogeneous. The aim of this study was to evaluate the clinical and prognostic characteristics of ...
Posttraumatic growth and death anxiety in caregivers of cancer patients: PHOENIX study
(Tubitak Scientific & Technical Research Council Turkey, 2020)
Background/aim: Posttraumatic growth (PTG) is defined as positive psychological changes following a challenging or traumatic life event. The purpose of this study is to define the predictors of PTG and death anxiety (DAN) ...
Double-edged sword: Granulocyte colony stimulating factors in cancer patients during the COVID-19 era
(Hospital Clinicas, Univ Sao Paulo, 2020)
Retrospective analysis of the effect of breast surgery on body posture in patients with early-stage breast cancer after cancer treatment (VENUS study) (Breast cancer and body posture)
(Turkiye Klinikleri, 2021)
Background/aim: The aim of this study was to determine whether breast surgery changes body posture in patients with early-stage breast cancer. Materials and methods: Study variables include age, side and localization of ...
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
(PMC, 2023)
Background: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which ...